KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) FCF Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed FCF Margin for 9 consecutive years, with 25.28% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, FCF Margin rose 2668.0% year-over-year to 25.28%, compared with a TTM value of 1.56% through Dec 2025, up 1335.0%, and an annual FY2025 reading of 39.64%, up 5143.0% over the prior year.
  • FCF Margin was 25.28% for Q2 2025 at Biocryst Pharmaceuticals, up from 19.01% in the prior quarter.
  • Across five years, FCF Margin topped out at 25.28% in Q2 2025 and bottomed at 58.13% in Q1 2024.
  • Average FCF Margin over 3 years is 7.61%, with a median of 2.54% recorded in 2023.
  • The sharpest move saw FCF Margin crashed -194bps in 2024, then skyrocketed 3912bps in 2025.
  • Year by year, FCF Margin stood at 2.54% in 2023, then crashed by -76bps to 4.48% in 2024, then surged by 665bps to 25.28% in 2025.
  • Business Quant data shows FCF Margin for BCRX at 25.28% in Q2 2025, 19.01% in Q1 2025, and 4.48% in Q4 2024.